Last reviewed · How we verify
Encapsulated FMT
Encapsulated FMT delivers a standardized consortium of live bacteria directly to the colon to restore a healthy microbiome composition.
Encapsulated FMT delivers a standardized consortium of live bacteria directly to the colon to restore a healthy microbiome composition. Used for Clostridioides difficile infection (recurrent or refractory), Inflammatory bowel disease (Crohn's disease or ulcerative colitis).
At a glance
| Generic name | Encapsulated FMT |
|---|---|
| Sponsor | King's College London |
| Drug class | Microbiota therapeutic |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Immunology |
| Phase | Phase 3 |
Mechanism of action
Fecal microbiota transplantation (FMT) works by introducing beneficial bacterial communities from screened donor stool into the patient's gut, where they colonize and rebalance the dysbiotic microbiome. The encapsulation protects the live bacteria from stomach acid and bile, allowing them to survive transit and establish in the lower intestine. This microbial restoration can reduce pathogenic organisms, restore metabolic function, and modulate immune responses.
Approved indications
- Clostridioides difficile infection (recurrent or refractory)
- Inflammatory bowel disease (Crohn's disease or ulcerative colitis)
Common side effects
- Gastrointestinal symptoms (abdominal pain, bloating, diarrhea)
- Nausea
- Fever
- Flatulence
Key clinical trials
- Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure (PHASE1)
- A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis (PHASE3)
- Transfer of FRozen Encapsulated Multidonor Stool Filtrate for Active Ulcerative COlitis (PHASE3)
- Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC) (PHASE2)
- Intestinal Microbiome Transplant in ALS (PHASE1, PHASE2)
- A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects (PHASE1)
- Fecal Microbiota Translantation (FMT) to Reduce Inflammation in PLWH: The Gutsy Pilot Study (PHASE2)
- STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Encapsulated FMT CI brief — competitive landscape report
- Encapsulated FMT updates RSS · CI watch RSS
- King's College London portfolio CI